ACE2 and pulmonary fibrosis: SARS-CoV infection decreases the expression of ACE2 (21), with possible relevance for the development of lung fibrosis reported in SARS patients months after their clearance of the viral infection (22–26); in fact, ACE2 exerts an anti-inflammatory role.